132 related articles for article (PubMed ID: 9710530)
21. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys.
Zhang Z; Miyoshi Y; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1396-401. PubMed ID: 9316852
[TBL] [Abstract][Full Text] [Related]
22. Recombinant adeno-associated virus vector expressing glial cell line-derived neurotrophic factor reduces ischemia-induced damage.
Tsai TH; Chen SL; Chiang YH; Lin SZ; Ma HI; Kuo SW; Tsao YP
Exp Neurol; 2000 Dec; 166(2):266-75. PubMed ID: 11085892
[TBL] [Abstract][Full Text] [Related]
23. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
24. Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse.
Frasson M; Picaud S; Léveillard T; Simonutti M; Mohand-Said S; Dreyfus H; Hicks D; Sabel J
Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2724-34. PubMed ID: 10509671
[TBL] [Abstract][Full Text] [Related]
25. Neurotrophic factor therapy for Parkinson's disease.
Rangasamy SB; Soderstrom K; Bakay RA; Kordower JH
Prog Brain Res; 2010; 184():237-64. PubMed ID: 20887879
[TBL] [Abstract][Full Text] [Related]
26. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
27. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
28. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
[TBL] [Abstract][Full Text] [Related]
29. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
Kobayashi S; Ogren SO; Hoffer BJ; Olson L
Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease.
Shingo T; Date I; Yoshida H; Ohmoto T
J Neurosci Res; 2002 Sep; 69(6):946-54. PubMed ID: 12205688
[TBL] [Abstract][Full Text] [Related]
31. Glial cell line-derived neurotrophic factor stimulates the morphological differentiation of cultured ventral mesencephalic calbindin- and calretinin-expressing neurons.
Widmer HR; Schaller B; Meyer M; Seiler RW
Exp Neurol; 2000 Jul; 164(1):71-81. PubMed ID: 10877917
[TBL] [Abstract][Full Text] [Related]
32. GDNF, a multispecific neurotrophic factor with potential therapeutic applications in neurodegenerative disorders.
Arenas E
Mol Psychiatry; 1996 Jul; 1(3):179-82. PubMed ID: 9118339
[No Abstract] [Full Text] [Related]
33. Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany.
Lücking CB; Lichtner P; Kramer ER; Gieger C; Illig T; Dichgans M; Berg D; Gasser T
Neurobiol Aging; 2010 Jan; 31(1):167-8. PubMed ID: 18436345
[TBL] [Abstract][Full Text] [Related]
34. Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease.
Choi JM; Hong JH; Chae MJ; Ngyuen PH; Kang HS; Ma HI; Kim YJ
Neurosci Lett; 2011 Apr; 493(3):97-101. PubMed ID: 21320571
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF.
McBride JL; Kordower JH
Prog Brain Res; 2002; 138():421-32. PubMed ID: 12432782
[No Abstract] [Full Text] [Related]
36. Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease.
Deng S; Deng H; Le W; Xu H; Yang H; Deng X; Lv H; Xie W; Zhu S; Jankovic J
Neurosci Lett; 2010 Jan; 468(3):195-7. PubMed ID: 19879328
[TBL] [Abstract][Full Text] [Related]
37. Use of growth factors for the treatment of Parkinson's disease.
Yasuda T; Mochizuki H
Expert Rev Neurother; 2010 Jun; 10(6):915-24. PubMed ID: 20518608
[TBL] [Abstract][Full Text] [Related]
38. The gene coding for glial cell line derived neurotrophic factor (GDNF) maps to chromosome 5p12-p13.1.
Schindelhauer D; Schuffenhauer S; Gasser T; Steinkasserer A; Meitinger T
Genomics; 1995 Aug; 28(3):605-7. PubMed ID: 7490108
[No Abstract] [Full Text] [Related]
39. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study.
Bäckman CM; Shan L; Zhang YJ; Hoffer BJ; Leonard S; Troncoso JC; Vonsatel P; Tomac AC
Mol Cell Endocrinol; 2006 Jun; 252(1-2):160-6. PubMed ID: 16644101
[TBL] [Abstract][Full Text] [Related]
40. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease.
Hunot S; Bernard V; Faucheux B; Boissière F; Leguern E; Brana C; Gautris PP; Guérin J; Bloch B; Agid Y; Hirsch EC
J Neural Transm (Vienna); 1996; 103(8-9):1043-52. PubMed ID: 9013392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
